The Effects of Topiroxostat, a Selective Xanthine Oxidoreductase Inhibitor, on Arterial Stiffness in Hyperuricemic Patients with Liver Dysfunction: A Sub-Analysis of the BEYOND-UA Study
Background: The effects of uric acid (UA)-lowering therapy with xanthine oxidoreductase (XOR) inhibitors on the development of cardiovascular diseases remain controversial. Based on recent findings that plasma XOR activity increased in liver disease conditions, we conducted a sub-analysis of the BEY...
Main Authors: | Yuya Fujishima, Hitoshi Nishizawa, Yusuke Kawachi, Takashi Nakamura, Seigo Akari, Yoshiyuki Ono, Shiro Fukuda, Shunbun Kita, Norikazu Maeda, Satoshi Hoshide, Iichiro Shimomura, Kazuomi Kario |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-02-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/11/3/674 |
Similar Items
-
Association of Mutations Identified in Xanthinuria with the Function and Inhibition Mechanism of Xanthine Oxidoreductase
by: Mai Sekine, et al.
Published: (2021-11-01) -
Comparative effects of topiroxostat and febuxostat on arterial properties in hypertensive patients with hyperuricemia
by: Kazuomi Kario, et al.
Published: (2021-02-01) -
Pro-Aging Effects of Xanthine Oxidoreductase Products
by: Maria Giulia Battelli, et al.
Published: (2020-09-01) -
Gender Differences in the Impact of Plasma Xanthine Oxidoreductase Activity on Coronary Artery Spasm
by: Ken Watanabe, et al.
Published: (2021-11-01) -
A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases
by: Ken Sato, et al.
Published: (2023-05-01)